More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

The following is a summary of “Barriers and facilitators to sustaining a lupus patient decision aid in regular rheumatology ...

May 23, 2024 — Treatment of autoimmune diseases like lupus has long relied on steroids to knock down the immune system, but more targeted therapies are currently undergoing clinical trials.

During the genocide, Gaza's lupus patients endured immense suffering, but after the ceasefire, there is hope to finally ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...